pharmaphorum

JULY 26, 2022

The 5th Annual Targeted Protein Degradation Summit returns to Boston as the most comprehensive, definitive event of the year, uniting 700+ large pharma, innovative biotech and world-renowned academics to discuss the full breadth of protein degrader drug development.

Drug Development 52

Drug Development 52

pharmaphorum

OCTOBER 12, 2020

In addition to the agenda, there will be two pre-conference interactive workshops on: Workshop A – 08.30 – 12.30 on How to Develop Physiologically Relevant Immune Competent Models in MPS, led by Pelin Candarlioglu, Investigator – Bioengineer/Cell Biologist, GSK. Workshop B – 13.30 – 17.30 — ENDS –.

Immunity 52

Immunity Immunization Drug Development 52

pharmaphorum

MARCH 14, 2022

Drug development. Exploratory development. Interactive Workshop on Friday 6 May 2022 on… Molecular and Cellular Pathophysiology of Pain Resolution. Workshop Leaders: Luda Diatchenko, Canada Research Chair in Human Pain Genetics, Department of Anesthesia, Faculty of Medicine, McGill University.

Compounding 52

Compounding Drug Development 52

FDA Law Blog: Biosimilars

MARCH 13, 2023

Bauer, Senior Regulatory Drug Expert & James E. Valentine — Incorporating patient and caregiver experiences into every phase of drug development has become increasingly prioritized during both development and review ( see, e.g. , previous coverage here ). By Larry J.

Drug Development 98

Drug Development Immunity Immunization 98

pharmaphorum

SEPTEMBER 2, 2020

Enhance capital efficiency to re-invest in drug development programs. Panel Discussions, Workshops and Case studies on how the industry is tackling the Covid-19 crisis and implement social distancing in the lab. 2 On-Demand Workshops to optimize your facility design, and implement digitalization & LIMS.

Drug Development 52

Drug Development 52

FDA Law Blog: Biosimilars

AUGUST 23, 2023

By the end of Q2 FY 2023, FDA will convene the first of a series of 5 public meetings or workshops with key stakeholders including patients, biopharmaceutical companies, DHT companies, and academia to gather input into issues related to the use of DHTs in regulatory decision-making.

Drug Development 52

Drug Development Documentation 52

pharmaphorum

JANUARY 27, 2022

The inaugural LNP Formulation & Process Development Summit is the industry’s first forum dedicated to bringing together drug developers within the LNP field to share the latest scientific breakthroughs on formulation and process development. Join 80+ of your peers and be part of this growing community.

Vaccines 52

Vaccines Drug Development 52

pharmaphorum

NOVEMBER 24, 2022

In 2021, LifeArc held a workshop (PDF) to explore the opportunities and challenges of repurposing drugs, developing a toolkit with the Medical Research Council (MRC). billion after selling a portion of its royalty interest in Merck & Co’s blockbuster cancer drug Keytruda to a pension fund.

Hospitals 58

Hospitals Compounding Drug Development 58

Express Pharma

APRIL 19, 2023

Championing formulation excellence Similar to Roquette’s other Innovation Centers, the new US facility is dedicated to furthering the field of pharma science through cross-industry collaboration, research-led product development and a drive to improve patients’ lives.

Dosage 52

Dosage Drug Development 52

pharmaphorum

APRIL 29, 2021

The scientific community will gather to discuss the translational challenges hindering drug developers working on different drug delivery approaches, and explore new approaches, such as gene therapy, to identify potential clinical success. 3-day Conference | June 28-30, 2021.

Drug Development 52

Drug Development 52

FDA Law Blog: Biosimilars

MAY 4, 2023

For example, in March 2023, FDA issued a Framework for the Use of Digital Health Technologies in Drug and Biological Product Development , which noted that FDA would publish guidance on the use of DHTs in both traditional and decentralized clinical trials.

Drug Development 59

Drug Development 59

Pulses

AUGUST 31, 2023

Table 2: Applications of Virtual Technology in Pharmacy Education AR VR MR XR Metaverse Virtual Laboratories √ √ 3D Anatomy and Physiology Visualization √ √ √ √ √ Drug Information and Interaction Visualizations √ √ √ Medication Administration Training √ √ √ Pharmacy Workflow and Practice Simulations √ Disease Simulation √ Medication Labeling and Packaging (..)

Medication Dispensing 78

Medication Dispensing Medication Labelling Packaging Compounding 78

Drug Channels

FEBRUARY 6, 2023

View the full agenda here.

Specialty Pharmacies 57

Specialty Pharmacies Hospitals Drug Development 57

pharmaphorum

OCTOBER 11, 2022

If you look at companies like Amazon and Google, the big tech companies, whenever they’ve gone into drug development on that side, they’ve found it incredibly hard. On the second day, he will be running a workshop on patient centricity. It’s very risky; it’s very hard to do.

Communication 96

Communication Diabetes Drug Development 96

Putting Patients First Blog

FEBRUARY 6, 2024

Rutta Chief Executive Officer 1 National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Forum on Drug Discovery, Development, and Translation. Innovation in drug research and development for prevalent chronic diseases: proceedings of a workshop.

Communication 40

Communication Documentation Drug Development 40

Quality Matters

NOVEMBER 10, 2022

and other countries to help guard against potential drug shortages and medicines supply chain disruptions. Implementing such innovation will take time, however, in part because of obstacles that some drug developers and manufacturers can face when considering whether to adopt PCM.

Drug Development 52

Drug Development 52

pharmaphorum

OCTOBER 7, 2020

Pepa has 15 years of combined experience in Regulatory Affairs (CMC) and multiple aspects of drug development and research and has participated in the approval of 15 original and biosimilar biologic license applications, focusing on microbiology product quality and sterility assurance aspects. Workshop: October 30th, 2020.

Biosimilars 52

Biosimilars Pharmaceutical Companies Pharmaceutical Companies Drug Development 52

Quality Matters

AUGUST 18, 2023

Though practices outlined in the guide are not official USP quality standards and are not intended to be binding or considered to be the only acceptable approach, they may be useful in developing PCM processes and facilitating adoption of PCM. Who should use the guide?

Drug Development 52

Drug Development 52